Mild to moderate ovarian hyperstimulation syndrome (OHSS) (WHO grade I or II) have been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Inversely, severe OHSS remains uncommon.
Uncommonly, cases of hypersensitivity reactions including pseudo-allergic/anaphylactoid reactions have been reported.
List of adverse reactions: The adverse reactions reported as follows are classified according to frequency of occurrence as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Immune system disorders: Uncommon: Systemic allergic/pseudo-allergic reactions including life-threatening anaphylaxis.
Nervous system disorders: Uncommon: Headache.
Gastrointestinal disorders: Uncommon: Nausea.
Reproductive system and breast disorders: Common: Mild to moderate OHSS (WHO grade I or II) can occur which is an intrinsic risk of the stimulation procedure (see Precautions). Uncommon: Severe OHSS (WHO grade III).
General disorders and administration site conditions: Common: Local reactions at the injection site (e.g. erythema, swelling and pruritus).
View ADR Monitoring Form